CD8A and glioblastoma: When considering the CCR6–CCL20 axis for therapeutic targeting in glioblastoma, CD8+CCR6+ T cells also migrate towards CCL20 and blockade of CCL20 or CCR6 has also been demonstrated to reduce neuroinflammation in murine models of subarachnoid hemorrhage [112,113].